Literature DB >> 28163231

Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders.

Sharon S Y Leung1, Thaigarajan Parumasivam1, Fiona G Gao1, Elizabeth A Carter2, Nicholas B Carrigy3, Reinhard Vehring3, Warren H Finlay3, Sandra Morales4, Warwick J Britton5, Elizabeth Kutter6, Hak-Kim Chan7.   

Abstract

This study aimed to develop inhalable powders containing phages active against antibiotic-resistant Pseudomonas aeruginosa for pulmonary delivery. A Pseudomonas phage, PEV2, was spray dried into powder matrices comprising of trehalose (0-80%), mannitol (0-80%) and l-leucine (20%). The resulting powders were stored at various relative humidity (RH) conditions (0, 22 and 60% RH) at 4°C. The phage stability and in vitro aerosol performance of the phage powders were examined at the time of production and after 1, 3 and 12 months storage. After spray drying, a total of 1.3 log titer reduction in phage was observed in the formulations containing 40%, 60% and 80% trehalose, whereas 2.4 and 5.1 log reductions were noted in the formulations containing 20% and no trehalose, respectively. No further reduction in titer occurred for powders stored at 0 and 22% RH even after 12 months, except the formulation containing no trehalose. The 60% RH storage condition had a destructive effect such that no viable phages were detected after 3 and 12 months. When aerosolised, the total lung doses for formulations containing 40%, 60% and 80% trehalose were similar (in the order of 105 pfu). The results demonstrated that spray drying is a suitable method to produce stable phage powders for pulmonary delivery. A powder matrix containing ≥40% trehalose provided good phage preservation and aerosol performances after storage at 0 and 22% RH at 4°C for 12 months.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  MDR; Multi-drug resistance; PEV2; Phage; Pulmonary infection; Spray drying

Mesh:

Substances:

Year:  2017        PMID: 28163231      PMCID: PMC5389863          DOI: 10.1016/j.ijpharm.2017.01.060

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  31 in total

Review 1.  Pharmacokinetic principles of bacteriophage therapy.

Authors:  Robert J H Payne; Vincent A A Jansen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  In vitro lung delivery of bacteriophages KS4-M and ΦKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis.

Authors:  L Golshahi; K H Lynch; J J Dennis; W H Finlay
Journal:  J Appl Microbiol       Date:  2010-09-28       Impact factor: 3.772

3.  Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection.

Authors:  Lisa A Carmody; Jason J Gill; Elizabeth J Summer; Uma S Sajjan; Carlos F Gonzalez; Ryland F Young; John J LiPuma
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

4.  Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections.

Authors:  Dieter Vandenheuvel; Abhishek Singh; Katrien Vandersteegen; Jochen Klumpp; Rob Lavigne; Guy Van den Mooter
Journal:  Eur J Pharm Biopharm       Date:  2013-01-23       Impact factor: 5.571

5.  Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections.

Authors:  Sharon S Y Leung; Thaigarajan Parumasivam; Fiona G Gao; Nicholas B Carrigy; Reinhard Vehring; Warren H Finlay; Sandra Morales; Warwick J Britton; Elizabeth Kutter; Hak-Kim Chan
Journal:  Pharm Res       Date:  2016-02-29       Impact factor: 4.200

6.  Phage therapy pharmacology: calculating phage dosing.

Authors:  Stephen Abedon
Journal:  Adv Appl Microbiol       Date:  2011       Impact factor: 5.086

7.  Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections.

Authors:  Laurent Debarbieux; Dominique Leduc; Damien Maura; Eric Morello; Alexis Criscuolo; Olivier Grossi; Viviane Balloy; Lhousseine Touqui
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

8.  Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells.

Authors:  Debebe Alemayehu; Pat G Casey; Olivia McAuliffe; Caitriona M Guinane; James G Martin; Fergus Shanahan; Aidan Coffey; R Paul Ross; Colin Hill
Journal:  mBio       Date:  2012-03-06       Impact factor: 7.867

9.  Isolation and characterization of a "phiKMV-like" bacteriophage and its therapeutic effect on mink hemorrhagic pneumonia.

Authors:  Zhenhui Cao; Jiancheng Zhang; Yan D Niu; Naizhong Cui; Yongsheng Ma; Fang Cao; Liji Jin; Zhen Li; Yongping Xu
Journal:  PLoS One       Date:  2015-01-23       Impact factor: 3.240

10.  Stability of Staphylococcus aureus phage ISP after freeze-drying (lyophilization).

Authors:  Maia Merabishvili; Chris Vervaet; Jean-Paul Pirnay; Daniel De Vos; Gilbert Verbeken; Jan Mast; Nino Chanishvili; Mario Vaneechoutte
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

View more
  22 in total

1.  Storage stability of inhalable phage powders containing lactose at ambient conditions.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Elizabeth Kutter; Sandra Morales; Warwick Britton; Jian Li; Hak-Kim Chan
Journal:  Int J Pharm       Date:  2019-01-31       Impact factor: 5.875

Review 2.  Phage therapy for respiratory infections.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Yu Lin; Sharon Sui Yee Leung; Hui Wang; Sandra Morales; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2018-08-07       Impact factor: 15.470

3.  Microencapsulation of phages to analyze their demeanor in physiological conditions.

Authors:  Esra Acar Soykut; Emine Kübra Tayyarcan; Şefika Evran; İsmail Hakkı Boyacı; İbrahim Çakır; Maha Khaaladi; Sami Fattouch
Journal:  Folia Microbiol (Praha)       Date:  2019-02-12       Impact factor: 2.099

Review 4.  Bacteriophage therapy in aquaculture: current status and future challenges.

Authors:  Ruyin Liu; Ganghua Han; Zong Li; Shujuan Cun; Bin Hao; Jianping Zhang; Xinchun Liu
Journal:  Folia Microbiol (Praha)       Date:  2022-03-19       Impact factor: 2.629

5.  Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection.

Authors:  Rachel Y Chang; Jennifer Wong; Ash Mathai; Sandra Morales; Elizabeth Kutter; Warwick Britton; Jian Li; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2017-09-07       Impact factor: 5.571

6.  Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation.

Authors:  Rachel Yoon Kyung Chang; Ke Chen; Jiping Wang; Martin Wallin; Warwick Britton; Sandra Morales; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

7.  Effect of storage temperature on the stability of spray dried bacteriophage powders.

Authors:  Sharon S Y Leung; Thaigarajan Parumasivam; An Nguyen; Thomas Gengenbach; Elizabeth A Carter; Nicholas B Carrigy; Hui Wang; Reinhard Vehring; Warren H Finlay; Sandra Morales; Warwick J Britton; Elizabeth Kutter; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2018-02-24       Impact factor: 5.571

8.  Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29.

Authors:  Nicholas B Carrigy; Sasha E Larsen; Valerie Reese; Tiffany Pecor; Melissa Harrison; Philip J Kuehl; Graham F Hatfull; Dominic Sauvageau; Susan L Baldwin; Warren H Finlay; Rhea N Coler; Reinhard Vehring
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

9.  Physicochemical properties of turanose and its potential applications as a sucrose substitute.

Authors:  Dong-Joo Han; Byung-Hoo Lee; Sang-Ho Yoo
Journal:  Food Sci Biotechnol       Date:  2021-03-26       Impact factor: 2.391

10.  Design and Optimization of a Temperature-Stable Dry Powder BCG Vaccine.

Authors:  Dominique N Price; Nitesh K Kunda; Rajaun Ellis; Pavan Muttil
Journal:  Pharm Res       Date:  2019-12-23       Impact factor: 4.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.